BACKGROUND INFORMATION ON THE PROCEDURE 
1. 
Submission of the dossier 
The company Boehringer Mannheim GmbH submitted on 21 April 1995 an application for Marketing 
Authorisation to the EMEA for Bondronat ampoules, through the centralised procedure, in accordance 
with  Article  6  of  Council  Regulation  (EEC)  No.  2309/93.  After  agreement  by  the  CPMP  on 
17 May 1995, this medicinal product is referred to List B in the Annex of the Council Regulation EEC 
No 2309/93, indent 7 as it contains a new active substance. 
The Rapporteur and Co-Rapporteur appointed by the CPMP,  were: 
Rapporteur:  
Dr. Gorm Jensen 
Co-Rapporteur:   Dr. Heribert Pittner 
Licensing status: 
The product was not licensed in any country inside or outside the EEC at the time of submission of the 
application. 
Steps taken for the assessment of the product 
The  Rapporteur’s  Assessment  Report  was  circulated  to  all  CPMP  Members  on  21  July  1995. 
The Co-Rapporteur’s Assessment Report was circulated to all CPMP Members on 11 July 1995. 
During  the  September  CPMP  meeting  a  draft  consolidated  list  of  questions  was  adopted  and 
circulated  for  comments  by  22  September  1995.  The  final  consolidated  list  of  questions  was 
sent to the Company on 28 September 1995. 
The  company  submitted 
20 November 1995. 
their  responses 
to 
the  consolidated 
list  of  questions  on 
The Rapporteur circulated the comments on the company’s responses to the list of questions to 
all CPMP Members on 22 December 1995. 
The  CPMP  during  its  meeting  of  13-15  February  1996,  in  the  light  of  the  current  scientific 
standards,  issued  a  positive  Opinion  for  granting  a  Marketing  Authorisation  to  Bondronat 
concentrate for solution for infusion on 14 February 1996. 
On 25 June 1996 the European Commission adopted a favourable Decision on the granting of a 
Marketing Authorisation for Bondronat. 
2. 
• 
• 
• 
• 
• 
• 
II 
1/1 
EMEA 2004 
 
 
